Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, Illinois.
Division of Geriatric and Palliative Medicine, UTHealth McGovern Medical School, Houston, Texas.
J Am Geriatr Soc. 2018 May;66(5):937-944. doi: 10.1111/jgs.15328. Epub 2018 Mar 6.
To describe medications that older hospice beneficiaries receive through Medicare Part D and assess patterns in Part D use for individuals admitted to hospice for cancer and noncancer causes.
Descriptive cohort analysis using the Surveillance, Epidemiology and End Results (SEER)-Medicare linked database.
U.S. hospice programs PARTICIPANTS: Part D-enrolled Medicare beneficiaries aged 66 and older who were admitted to hospice and died while under hospice care between January 1, 2008, and December 31, 2013 (N = 88,957).
We determined the 25 most commonly dispensed medications and the prevalence of at least 1 dispensing through Part D after hospice admission. The prevalence and temporal trends in receipt of opioid analgesics and several preventative medication classes are described.
More than half of individuals admitted to hospice for cancer (53.5%) and noncancer causes (52.9%) received at least 1 medication through Part D after hospice admission. The prevalence of receiving at least 1 Part D medication after admission was greatest in individuals admitted for debility or failure to thrive (63.5%) and dementia (61.5%) and lowest in those admitted for ischemic stroke (35.4%) and renal disease (36.0%). Beta-blockers, angiotensin-converting enzyme inhibitors, proton pump inhibitors, and statins were among the most common preventative drug classes received overall, although prevalence differed according to admission diagnosis. Nearly 1 in 6 individuals received opioids through Part D after admission, with prevalence steadily decreasing over the study period.
Receipt of medications through Medicare Part D after hospice admission is common, particularly for preventative medications, and varies according to admission diagnosis. Further research aimed at better understanding individual-, provider-, and healthcare system-level contributors to nonpalliative medication use in the hospice population is warranted.
描述 Medicare 部分 D 中接受的老年临终关怀受益人的药物,并评估因癌症和非癌症原因入住临终关怀的个体对部分 D 的使用模式。
使用监测、流行病学和最终结果(SEER)-医疗保险链接数据库进行描述性队列分析。
美国临终关怀计划。
2008 年 1 月 1 日至 2013 年 12 月 31 日期间,年龄在 66 岁及以上并登记参加 Medicare 部分 D、入住临终关怀并在临终关怀期间死亡的患者(N = 88957)。
我们确定了 25 种最常配药的药物,并确定了至少有 1 种通过部分 D 配药在入住临终关怀后的流行率。描述了阿片类镇痛药和几种预防药物类别的接受率和时间趋势。
超过一半因癌症(53.5%)和非癌症原因(52.9%)入住临终关怀的个体在入住临终关怀后至少通过部分 D 接受了 1 种药物。在因虚弱或衰竭而入住(63.5%)和痴呆(61.5%)的个体中,接受至少 1 种部分 D 药物治疗的比例最高,而在因缺血性中风(35.4%)和肾脏疾病(36.0%)入住的个体中比例最低。β受体阻滞剂、血管紧张素转换酶抑制剂、质子泵抑制剂和他汀类药物是总体上最常见的预防药物类别,但根据入院诊断,流行率有所不同。近 1/6 的个体在入住临终关怀后通过部分 D 接受阿片类药物治疗,研究期间这一比例稳步下降。
在入住临终关怀后通过 Medicare 部分 D 接受药物治疗很常见,特别是对于预防药物,且根据入院诊断而有所不同。需要进一步研究,旨在更好地了解个体、提供者和医疗保健系统层面导致临终关怀人群中使用非姑息性药物的因素。